Versant Venture Capital VI, L.P. sold $1.5M of GLUE
owner at Monte Rosa Therapeutics, Inc.. 157,895 shares at an average of $9.44, traded Oct 28, 2024, filed Oct 30, 2024.
Score components
- +12Role10% owner
- +25Trade size$1.5M at market
- 0Share of holdings soldSold 7.5% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.4%, 3m -35.0%, 6m -46.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-119051, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | SOpen-market sale Common Stockindirect: See Footnote | -89,990 | $9.66 | $869k | 2,007,948 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stock | -1,019,867 | $0.00 | $0 | 4,079,469 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | +20,397 | $0.00 | $0 | 20,397 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | -20,397 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | +17,595 | $0.00 | $0 | 17,595 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | -17,595 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | -366,590 | $0.00 | $0 | 1,641,358 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | +5,499 | $0.00 | $0 | 5,499 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | -5,499 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | +5,454 | $0.00 | $0 | 5,454 | Oct 30, 2024 |
| Oct 28, 2024 | JOther Common Stockindirect: See Footnote | -5,454 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 29, 2024 | SOpen-market sale Common Stockindirect: See Footnote | -52,305 | $9.08 | $475k | 1,589,053 | Oct 30, 2024 |
| Oct 29, 2024 | SOpen-market sale Common Stockindirect: See Footnote | -15,600 | $9.41 | $147k | 1,573,453 | Oct 30, 2024 |
Related signals
Other insiders at Monte Rosa Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Matthew Bowen Principal Accounting Officer | $137 13 shares | -0% | |
| 15Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Edmund Dunn Principal Accounting Officer | $9,174 2,062 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.